Vishwanath Ganesan
Hematology & Oncology · Los Angeles, CANPI 1679156368
Payments from drug & device makers
Across 61 payments — averaging $44.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$356
- Gilead$292
- AstraZeneca$283
- Incyte Corporation$245
- Aadi Bioscience, Inc.$158
- Karyopharm Therapeutics Inc.$156
- plus $1K from 20 others
What the payments were for
- Food & beverage$2,52694%
- Education$1756%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 8 | $356 |
| Gilead(2 entities) | 3 | $292 |
| AstraZeneca(2 entities) | 4 | $283 |
| Incyte Corporation | 6 | $245 |
| Aadi Bioscience, Inc. | 1 | $158 |
| Karyopharm Therapeutics Inc. | 2 | $156 |
| Merck | 5 | $128 |
| Daiichi Sankyo Inc. | 5 | $125 |
| Sobi, Inc | 1 | $124 |
| AbbVie | 3 | $123 |
| GSK | 1 | $99 |
| Novartis | 3 | $90 |
| Coherus Oncology, Inc. | 4 | $90 |
| EMD Serono, Inc. | 2 | $84 |
| Agios Pharmaceuticals, Inc. | 2 | $47 |
| Jazz Pharmaceuticals Inc. | 1 | $33 |
| Syndax Pharmaceuticals, Inc. | 1 | $32 |
| Exelixis Inc. | 1 | $31 |
| Rigel Pharmaceuticals, Inc. | 1 | $31 |
| Bristol Myers Squibb | 1 | $30 |
| Genentech USA, Inc. | 1 | $28 |
| Beone Medicines USA, Inc. | 1 | $28 |
| Blueprint Medicines Corporation | 1 | $28 |
| Eisai Inc. | 1 | $24 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
| Pfizer | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,701 in reported general payments places this provider in the 35th percentile of 1,363 hematology & oncology providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Sucralfate | 11 | $4,709 |
| Atorvastatin Calcium | 55 | $552 |
| Fluticasone Propionate | 14 | $529 |
| Gabapentin | 18 | $417 |
| Losartan Potassium | 29 | $369 |
| Tamsulosin Hcl | 13 | $336 |
| Metoprolol Succinate | 12 | $314 |
| Metformin Hcl | 26 | $291 |
| Rosuvastatin Calcium | 16 | $268 |
| Omeprazole | 12 | $207 |
| Tizanidine Hcl | 12 | $152 |
| Lisinopril | 16 | $147 |
| Pantoprazole Sodium | 12 | $130 |
| Levothyroxine Sodium | 12 | $124 |
| Amlodipine Besylate | 36 | $98 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Los Angeles
- David BerzLos Angeles$43.3M
- Nicholas McAndrewLos Angeles$22.9M
- Antoni RibasLos Angeles$13M
- Gary SchillerLos Angeles$11.9M
- Matthew RettigLos Angeles$8.2M
- Lasika SeneviratneLos Angeles$8.1M
- Gary BuchschacherLos Angeles$7.9M
- Edward GaronLos Angeles$7.9M
- Gottfried KonecnyLos Angeles$7.6M
- Sven de VosLos Angeles$6.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.